Similarly, chronic myeloid leukemia (CML) cells have been shown to express RHAMM/CD168, inducing specific CD8+ T-cell responses and suggesting the potential for RHAMM-R3-directed effector T cells in immunotherapy [107]. Here, HMMR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.